Shuttle Pharmaceuticals Holdings, Inc. SHPH

Full chart Compare
Set alert

Price alert · SHPH

All alert types
5.15 USD +0.20 (+4.04%)

At closeNov 3, 2026, 4:02 PM EST

5.15 0.00 0.00%

After hours · Nov 3, 4:02 PM ET

4.48 Day range 5.15
2.58 52-week range 44.40
YTD
-71.39%
1 year
-83.39%
Market cap
24.54M
EPS (ttm)
-16.87
Shares out
3.66M
YTD return
-71.39%
1-year return
-83.39%
Volume
54.48K
Avg volume
70.97K
Open
4.53
Previous close
4.95
Day's range
4.48 – 5.15
52-week range
2.58 – 44.40
Beta
0.74

2Y -395.00 (-98.75%)

0200400Jan 25Jun 25Nov 25Mar 26Aug 265.00

Key statistics

Enterprise value
1.20M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.35
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-2.49M
Total cash
2.34M
Total debt
1.16M
Return on equity
-186.00%
Short % of float
27.91%
50-day average
1.06
200-day average
2.42

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
SHPH Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
SHPH Net income — quarterly -3.15M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
SHPH EPS — quarterly -3.10
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

About Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on SHPH — it syncs with the Stock Master app.

Insider holders

SHPH insider holders
InsiderRelationLatest transactionDateShares held
ADKINS WILLIAM HFounderSaleDec 28, 2022184,071
BROWN MILTONDirectorSaleDec 12, 20231,094,610
DRITSCHILO ANATOLYChief Executive OfficerStock GiftAug 13, 20230
DRITSCHILO PETERPresidentSaleDec 28, 20226,560
JACOBS BETTEDirectorSaleDec 12, 202327,064
JUNG MIRAOfficerSaleDec 28, 20221,071,390

Institution ownership

SHPH institution ownership
Holder% heldSharesValueReported
HRT Financial LP0.71%25,86618.49KSep 29, 2024
Tower Research Capital LLC (TRC)0.11%3,8582.76KSep 29, 2024
Federation Des Caisses Desjardins Du Quebec0.00%6345Sep 29, 2024
Bank of America Corporation0.00%96Sep 29, 2024

Fund ownership

SHPH fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.09%3,1512.25KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.02%616440Oct 30, 2024
Fidelity Series Total Market Index Fund0.01%501358Oct 30, 2024